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Conclusion: Although BMI has been reported to be correlated to baro-
receptor sensibility, it doesn’t seem to influence HRV and HRT parameters in
hypertensive patients. The interpretation of HRV and HRT in hypertension
doesn’t need adjustment to BMI.
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Introduction: Heart rate variability (HRV) abnormalities have been sug-
gested to be associated with higher risk of occurrence of cardio-vascular
events. Several studies noticed HRV abnormalities in systemic hypertension.
Aim: The aim of this prospective study is to evaluate the effect of antihy-
pertensive treatment on temporal and spectral parameters of heart rate vari-
ability.
Methods: This study included 85 patients ( mean age 57±11 years and sex
ratio 0.88) followed up for hypertension. They underwent 24 hours Holter
recording and 24 hours ambulatory blood pressure monitoring (ABPM).
Thirty nine patients (45%) received diuretics, 49 patients (57%) were on ACE
or ARB, 42 patients (49%) were on B blockers, 39 patients (45%) received
calcium channel inhibitors and 8 patients (9%) were on central antihyperten-
sive treatment. Patients in different therapeutic groups were similar regarding
demographic characteristics and arterial systolic and diastolic pressure
Results: There was no significant difference in HRV parameters between
patients receiving ACE/ARB, those on calcium channel blockers, on diuretics
and patients receiving central antihypertensive treatment. We noticed that
HRV parameters tended to be more altered in patients receiving B blockers.
Conclusion: In our study most classes of antihypertension treatment don’t
affect the HRV parameters. The effect of B blockers is contreversial. Their
deleterious effect on HRV must be verified by larger studies.
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Objectives: to investigate relations between obesity, plasma cholesterol
level and structural changes of the heart in patients with combined ischemic
heart disease (IHD) and arterial hypertension (AH).
Material and methods: 35 patients (24 males and 11 females) with long-
standing IHD and AH were enrolled in the study. The average age of patients
was 54,2+8,1 years. All patients underwent routine clinical examinations
including anthropometry, office blood pressure (BP) measurement, echocar-
diography and measurement of fasting total cholesterol (TC) in plasma. Left
ventricular myocardial mass (LVMM) was calculated by Penn Convention
formula. Indexation of LVMM was made by height in 2.7 power. Left atrium
diameter (LAD) was measured in anterior-posterior direction. All patients
received conventional anti-ischemic and anti-hypertensive treatment regularly.
Results: Any significant correlations between BP in treated patients and
characteristics of cardiac remodeling were not found. Meanwhile, average BP
correlated significantly with BMI (r=0.51, p=0.002) and TC (r=0.59,
p<0.001). Moreover, increased BMI wasn’t associated with specific changes
in the heart structure except LAD (r=0.61, p<0.001), and LAD itself correlated
positively with LVMM index2.7 (r=0.72, p<0.001) and negatively with ejection
fraction of LV (r=–0.49, p=0.003). Interestingly, that age of patients correlated
only with diameter of ascending aorta (r=0.46, p=0.06) which increasing is
probably associated with pronounced atherosclerosis. Sex of patients had
impact on few values. Compare to females in this study males had higher
height (173.7+4.3 vs. 167.0+4.4 cm, p<0.001) and diameter of ascending aorta
(35.1+4.9 vs. 31.4+4.1 cm).
Conclusion: AH is more resistant for conventional treatment if associated
with obesity and hypercholesterolemia. Increasing of BMI is related to spe-
cific type of cardiac remodeling – namely – enlargement of left atrium (known
marker of pronounced diastolic dysfunction). Large left atrium is often com-
bined with LV hypertrophy and systolic dysfunction. Finally, diameter of
ascending aorta is more likely increased in males and in elderly age.
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The aim of the study was to estimate how the ankle-brahial blood pressure
index (ABPI) correlates with cardiovascular events at hypertensive patients
(pts) with or without metabolic syndrome (MS).
Methods: 40 hypertensive pts(mean age =57.1+/–7.5 years, 52.5% males)
– group 1 and 40 hypertensive pts with MS, matched for age and sex(mean
age =58.7+/–7.2 years, 55% males) – group 2. ABPI was evaluated using
ultrasound assessment of blood flow in posterior tibial artery and brachial
artery. ABPI smaller than 1 was considered abnormal. All pts were evaluated
during one year in order to detect the following complications: unstable
angina(UA),non-ST-segment elevation myocardial infarction(NSTEMI), tran-
sient ischemic stroke(TIS),ischemic stroke(IS).
Results: In group 1, 17 pts(42.5%) had reduced ABPI:0.62+/–0.24. In
group 2, 19 pts (47.5%) had reduced ABPI:0.54+/–0.16. The difference is not
significantly statistic between the two groups(p=0.12). In group1,UA was sig-
nificantly associated with reduced ABPI(0.64+/–0.26 vs 0.91+/–0.18,
p=0.04).In the same group,TIS was found in a significantly higher proportion at
pts with reduced ABPI(0.61+/–0.12 vs 1.02+/0.14, p=0.001). In group 2,UA was
also significantly associated with reduced ABPI (0.56 +/–0.11 vs 0.88+/–0.14,
p=0.02). NSTEMI was significantly more frequent at pts with reduced
ABPI(0.52+/–0.12 vs 0.93+/–0.16, p=0.002). In the same group, TIS was
found in a significantly higher proportion at pts with reduced ABPI (0.58+/–
0.14 vs 0.96+/–0.12, p=0.03).
Conclusions: Hypertensive pts with MS have reduced ABPI in a higher
but not significant proportion than hypertensive pts without MS. Reduced
ABPI seems to predict a worse mid term outcome (one year) concerning car-
diovascular events at hypertensive pts, especially with MS. Moreover, reduced
ABPI appears to have more powerful mid term prognostic value for incidence
of acute coronary syndrome without ST-segment elevation at hypertensive pts
with MS.
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The aim of this study was to determine the plasma levels of Matrix metallopro-
teinases (MMPs): MMP-2, MMP-3, MMP-9, and their inhibitors (TIMPs):TIMP-1,
and TIMP-2 in hypertensive patients and healthy subjects. The study has involved
40 hypertensive patients and 41 adult healthy controls. The mean plasma activity
of pro-MMP9 in the hypertensive group and the control group were significantly
different (15.33±12.93 vs 90.38±97.49 103 densitometric units/ul; p<0.05). The
